January 1, 2011 Journal article Open Access

Barak; Paola Ferrari; Angelo Carpi; Andrea Nicolini; Paolo Miccoli; Massimo Conte; Michael J. Duffy; Giorgio Rossi

JSON-LD (schema.org) Export

{
  "@context": "https://schema.org/", 
  "@id": "https://doi.org/10.2741/e348", 
  "@type": "ScholarlyArticle", 
  "creator": [
    {
      "@type": "Person", 
      "name": "Barak"
    }, 
    {
      "@type": "Person", 
      "name": "Paola Ferrari"
    }, 
    {
      "@type": "Person", 
      "name": "Angelo Carpi"
    }, 
    {
      "@type": "Person", 
      "name": "Andrea Nicolini"
    }, 
    {
      "@type": "Person", 
      "name": "Paolo Miccoli"
    }, 
    {
      "@type": "Person", 
      "name": "Massimo Conte"
    }, 
    {
      "@type": "Person", 
      "name": "Michael J. Duffy"
    }, 
    {
      "@type": "Person", 
      "name": "Giorgio Rossi"
    }
  ], 
  "datePublished": "2011-01-01", 
  "description": "Metastatic colorectal and other locally advanced gastrointestinal (G.I.) cancers often recur after curative resection. Many mechanisms of tumor growth and/or immune escape by residual cancer cells may provoke tumor progression. Long-term, cytostatic action with repeated post-adjuvant administration of 5-fluorouracil (FU)-leucovorin (LV) cycles may interrupt or downregulate these mechanisms and favor the recovery and/or increase the immune system activity. Seventy patients were considered. An active prospective cohort including 21 patients (study group) was matched in a 1:1 ratio with a retrospective parallel control group of 21 patients. The study group received long-term repeated post-adjuvant administration of 5-FU-LV cycles, while the matched control group was conventionally treated. Statistical analysis was performed by Kaplan-Meier method and Cox's proportional hazard regression model. The five-year disease-free survival (DFS) was 77.0 + 10.1 % and 31.7 + 10.6 % (p = 0.001; hazard ratio (HR) 5.3, 95 % C.I.: 1.7-16.1, p = 0.003), while the five-year overall survival (OS) was 88.0 + 8.1 % and 37.0 + 10.7 % (p = 0.001; HR 8.9, 95 % C.I.: 2.0-39.9, p = 0.004) in the study group and in matched controls respectively. These findings suggest a relevant improvement in the outcome of this population by an intermittent and prolonged cytostatic effect with 5-FU-LV.", 
  "headline": "Additional 5-FU-LV significantly increases survival in gastrointestinal cancer.", 
  "identifier": "https://doi.org/10.2741/e348", 
  "image": "https://zenodo.org/static/img/logos/zenodo-gradient-round.svg", 
  "inLanguage": {
    "@type": "Language", 
    "alternateName": "eng", 
    "name": "English"
  }, 
  "keywords": [
    "General Immunology and Microbiology", 
    "General Biochemistry, Genetics and Molecular Biology"
  ], 
  "license": "", 
  "name": "Additional 5-FU-LV significantly increases survival in gastrointestinal cancer.", 
  "url": "https://www.openaccessrepository.it/record/119229"
}